[Solved]: During a shared decision-making conversation, a…

During a shared decision-making conversation, a patient with moderate-to-severe CD raises concerns about issues such as the time needed to see improvement in symptoms and when changes in therapy may be needed. How would the timing of assessment of treatment targets and therapeutic decisions be best described in the STRIDE-II treat-to-target strategy? * A. Treatment response is monitored every 3 months with changes in therapy based on failure to achieve long-term (>6 months) goals, regardless of the drug selected B. Treatment is monitored regularly with changes in therapy dependent upon failure to achieve transmural healing C. Treatment decisions are made based on achievement of shortterm (❤️ months), intermediate (3-6 months), and long-term (>6 months) goals, with timing adjusted for the drug selected D. Treatment response is monitored monthly and changes in therapy are based primarily on induction and maintenance of clinical remission